Nifty
:
22780.25
Sensex
:
72771.72
-360.25 (-1.56%)
-1124.02 (-1.52%)
Nifty
Sensex
:
:
22780.25
72771.72
-360.25 (-1.56%)
-1124.02 (-1.52%)

Cohance Lifesciences Ltd.

Pharmaceuticals & Drugs - Global

Rating :
37/99

BSE: 543064 | NSE: COHANCE

NSE BSE
459.25
25-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  456.3
  •  460
  •  450.05
  •  454.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  557235
  •  252393783.85
  •  917.85
  •  266.7

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 17,563.13
  • 165.33
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 17,673.14
  • N/A
  • 4.56

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 57.49%
  • 7.32%
  • 7.71%
  • FII
  • DII
  • Others
  • 6.5%
  • 19.99%
  • 0.99%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 11.43
  • 29.22

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -6.00
  • 1.02

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -16.96
  • -15.80

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 44.30
  • 94.33

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 9.84
  • 10.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 39.91
  • 52.57

Earnings Forecasts:

(Updated: 27-09-2026)
Description
2026
2027
2028
2029
Adj EPS
4.69
7.42
12.09
16.21
P/E Ratio
97.92
61.89
37.99
28.33
Revenue
2203.81
2339.46
2988.98
3452.97
EBITDA
426.99
425.53
805.97
879.45
Net Income
179.23
288.94
366.64
617.47
ROA
3.2
9.57
11.76
7.28
P/B Ratio
4.49
4.33
3.81
3.53
ROE
4.74
5.08
9.77
16.87
FCFF
135.09
85.3
64.3
3237.34
FCFF Yield
0.77
0.49
0.37
18.42
Net Debt
74.51
-185.2
-521.73
-379.4
BVPS
102.24
106.08
120.55
130.23

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
422.26
549.31
-23.13%
619.12
840.42
-26.33%
544.55
676.23
-19.47%
555.57
603.77
-7.98%
Expenses
421.10
437.30
-3.70%
520.44
611.20
-14.85%
449.20
438.86
2.36%
434.62
398.40
9.09%
EBITDA
1.16
112.01
-98.96%
98.68
229.22
-56.95%
95.35
237.37
-59.83%
120.95
205.37
-41.11%
EBIDTM
0.27%
20.39%
15.94%
27.27%
17.51%
35.10%
21.77%
34.01%
Other Income
12.25
14.17
-13.55%
-1.84
12.05
-
6.16
21.56
-71.43%
15.60
16.19
-3.64%
Interest
6.74
10.18
-33.79%
9.19
10.45
-12.06%
9.11
10.80
-15.65%
8.76
9.61
-8.84%
Depreciation
49.54
45.14
9.75%
51.23
54.17
-5.43%
46.94
43.56
7.76%
44.02
37.79
16.49%
PBT
-42.87
62.76
-
19.91
160.87
-87.62%
40.60
204.57
-80.15%
83.77
174.16
-51.90%
Tax
2.32
16.36
-85.82%
11.60
43.72
-73.47%
11.58
51.09
-77.33%
17.38
35.92
-51.61%
PAT
-45.19
46.40
-
8.31
117.15
-92.91%
29.02
153.48
-81.09%
66.39
138.24
-51.97%
PATM
-10.70%
8.45%
1.34%
13.94%
5.33%
22.70%
11.95%
22.90%
EPS
-0.63
1.28
-
0.51
4.73
-89.22%
0.96
6.01
-84.03%
1.94
5.44
-64.34%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Net Sales
2,141.50
2,268.55
2,608.50
1,051.35
1,340.33
1,320.22
1,009.72
833.79
377.83
Net Sales Growth
-19.79%
-13.03%
148.11%
-21.56%
1.52%
30.75%
21.10%
120.68%
 
Cost Of Goods Sold
634.77
657.16
813.79
311.86
402.97
394.05
297.56
225.32
101.46
Gross Profit
1,506.73
1,611.39
1,794.71
739.49
937.36
926.17
712.16
608.47
276.37
GP Margin
70.36%
71.03%
68.80%
70.34%
69.94%
70.15%
70.53%
72.98%
73.15%
Total Expenditure
1,825.36
1,841.56
1,811.44
645.54
766.17
738.50
566.72
449.03
206.28
Power & Fuel Cost
-
122.51
107.49
48.30
73.93
59.55
44.20
38.23
18.06
% Of Sales
-
5.40%
4.12%
4.59%
5.52%
4.51%
4.38%
4.59%
4.78%
Employee Cost
-
507.71
447.81
135.23
118.25
100.48
76.23
65.10
29.63
% Of Sales
-
22.38%
17.17%
12.86%
8.82%
7.61%
7.55%
7.81%
7.84%
Manufacturing Exp.
-
285.60
215.67
88.37
109.62
129.24
105.31
83.89
35.11
% Of Sales
-
12.59%
8.27%
8.41%
8.18%
9.79%
10.43%
10.06%
9.29%
General & Admin Exp.
-
148.72
93.37
27.11
33.87
28.99
27.73
25.97
12.62
% Of Sales
-
6.56%
3.58%
2.58%
2.53%
2.20%
2.75%
3.11%
3.34%
Selling & Distn. Exp.
-
53.80
42.72
10.46
17.64
19.80
10.53
9.43
6.72
% Of Sales
-
2.37%
1.64%
0.99%
1.32%
1.50%
1.04%
1.13%
1.78%
Miscellaneous Exp.
-
66.06
90.59
24.21
9.90
6.37
5.16
1.08
2.69
% Of Sales
-
2.91%
3.47%
2.30%
0.74%
0.48%
0.51%
0.13%
0.71%
EBITDA
316.14
426.99
797.06
405.81
574.16
581.72
443.00
384.76
171.55
EBITDA Margin
14.76%
18.82%
30.56%
38.60%
42.84%
44.06%
43.87%
46.15%
45.40%
Other Income
32.17
34.09
69.21
61.91
46.36
92.38
14.24
18.12
0.60
Interest
33.80
37.24
41.06
7.45
12.81
8.53
11.67
23.07
2.79
Depreciation
191.73
187.33
166.80
54.60
47.99
39.10
31.64
23.51
11.50
PBT
101.41
236.51
658.41
405.67
559.73
626.48
413.94
356.30
157.87
Tax
42.88
56.92
158.39
105.39
148.44
213.78
105.33
87.51
48.59
Tax Rate
42.28%
27.49%
24.65%
25.98%
26.52%
34.12%
25.45%
24.56%
30.78%
PAT
58.53
179.23
487.34
300.28
411.29
453.80
362.34
317.00
109.27
PAT before Minority Interest
106.23
150.12
484.24
300.28
411.29
453.80
362.34
317.00
109.27
Minority Interest
47.70
29.11
3.10
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
2.73%
7.90%
18.68%
28.56%
30.69%
34.37%
35.89%
38.02%
28.92%
PAT Growth
-87.14%
-63.22%
62.30%
-26.99%
-9.37%
25.24%
14.30%
190.11%
 
EPS
1.53
4.68
12.74
7.85
10.75
11.86
9.47
8.29
2.86

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Shareholder's Funds
3,911.29
3,648.82
2,050.67
1,735.18
1,527.18
1,180.81
844.76
590.29
Share Capital
38.26
25.46
25.46
25.46
25.46
25.46
12.73
0.00
Total Reserves
3,854.95
3,541.58
2,023.24
1,709.73
1,501.72
1,155.35
832.03
577.56
Non-Current Liabilities
1,047.24
982.12
86.03
71.79
92.11
73.91
127.68
35.12
Secured Loans
50.48
129.75
0.00
4.56
28.44
35.59
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
91.25
0.00
Long Term Provisions
0.40
0.26
0.00
8.30
8.89
6.65
8.31
5.95
Current Liabilities
645.93
705.41
117.40
303.09
347.52
321.51
319.85
190.67
Trade Payables
284.58
268.43
42.35
70.09
105.90
82.93
71.06
53.57
Other Current Liabilities
223.19
313.25
21.23
19.84
29.54
28.57
27.51
19.47
Short Term Borrowings
74.43
70.65
38.58
64.60
67.13
105.64
94.04
82.79
Short Term Provisions
63.73
53.08
15.24
148.56
144.94
104.36
127.24
34.83
Total Liabilities
5,727.00
5,480.41
2,254.10
2,110.06
1,966.81
1,576.23
1,292.29
816.08
Net Block
3,368.74
3,107.29
669.62
663.33
534.19
441.16
356.74
270.90
Gross Block
4,230.69
3,788.42
929.16
875.60
693.81
569.62
456.66
347.41
Accumulated Depreciation
861.95
681.13
259.54
212.27
159.62
128.46
99.91
76.51
Non Current Assets
3,899.04
3,686.93
1,000.89
954.70
701.66
909.68
781.17
393.28
Capital Work in Progress
177.73
334.42
179.08
165.09
29.99
96.32
101.71
111.07
Non Current Investment
262.23
145.42
130.58
117.10
117.10
361.19
307.46
0.07
Long Term Loans & Adv.
71.47
86.45
21.61
9.19
13.07
10.85
15.06
11.02
Other Non Current Assets
18.87
13.35
0.00
0.00
7.30
0.16
0.20
0.22
Current Assets
1,796.26
1,758.17
1,253.21
1,155.37
1,265.16
666.54
511.12
422.80
Current Investments
266.32
191.74
773.90
418.94
481.22
180.59
30.67
7.06
Inventories
562.23
467.37
231.20
312.81
283.42
201.08
174.87
157.10
Sundry Debtors
681.01
772.10
133.66
110.94
236.37
102.38
117.20
147.50
Cash & Bank
59.66
102.48
50.50
68.01
47.31
9.65
14.07
12.90
Other Current Assets
227.04
32.66
11.90
11.46
216.84
172.83
174.30
98.24
Short Term Loans & Adv.
185.30
191.82
52.05
233.21
205.97
161.00
165.17
85.18
Net Current Assets
1,150.33
1,052.76
1,135.81
852.28
917.64
345.04
191.27
232.13
Total Assets
5,695.30
5,445.10
2,254.10
2,110.07
1,966.82
1,576.22
1,292.29
816.08

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Cash From Operating Activity
368.32
673.35
384.77
457.20
330.00
382.55
406.92
50.40
PBT
207.04
642.63
405.67
559.73
667.59
467.67
404.51
157.87
Adjustment
208.29
207.36
17.14
37.46
40.63
36.48
34.60
13.93
Changes in Working Capital
20.76
-0.73
71.91
5.77
-193.97
-12.17
54.21
-88.33
Cash after chg. in Working capital
436.09
849.26
494.72
602.96
514.26
491.98
493.33
83.47
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-67.77
-175.91
-109.95
-145.76
-184.26
-109.44
-86.41
-33.06
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-254.57
-389.70
-362.35
-195.01
-136.14
-311.40
-413.45
-65.48
Net Fixed Assets
-142.74
-1,964.05
-230.17
-154.01
-57.86
-107.57
-99.89
Net Investments
-69.95
-224.11
-182.51
-110.17
-173.65
-149.92
-269.19
Others
-41.88
1,798.46
50.33
69.17
95.37
-53.91
-44.37
Cash from Financing Activity
-165.15
-327.40
-39.99
-241.95
-156.48
-75.66
7.32
25.98
Net Cash Inflow / Outflow
-51.40
-43.75
-17.57
20.24
37.38
-4.51
0.79
10.90
Opening Cash & Equivalents
96.65
138.32
64.80
44.56
7.18
11.70
10.90
0.00
Closing Cash & Equivalent
49.14
96.65
47.23
64.80
44.56
7.18
11.70
10.90

Financial Ratios

Standalone /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Book Value (Rs.)
101.76
140.10
80.47
68.16
59.99
46.39
33.18
0.00
ROA
2.68%
12.52%
13.76%
20.18%
25.62%
21.52%
25.50%
13.39%
ROE
4.02%
17.25%
15.87%
25.21%
33.52%
30.47%
37.80%
18.92%
ROCE
6.12%
22.80%
21.22%
33.41%
45.92%
36.19%
44.55%
23.87%
Fixed Asset Turnover
0.57
1.11
1.17
1.71
2.09
1.97
2.07
1.09
Receivable days
116.90
63.37
42.46
47.25
46.80
39.69
57.94
142.49
Inventory Days
82.83
48.87
94.43
81.11
66.93
67.95
72.66
151.76
Payable days
153.58
69.70
65.80
79.70
87.45
94.44
49.88
86.75
Cash Conversion Cycle
46.15
42.55
71.09
48.66
26.27
13.19
80.72
207.50
Total Debt/Equity
0.04
0.07
0.02
0.04
0.06
0.12
0.22
0.14
Interest Cover
6.56
16.65
55.45
44.69
79.29
36.48
16.45
57.60

Annual Reports:

FY 2026
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020

News Update:


  • USFDA concludes inspection at Cohance Lifesciences’ Andhra Pradesh facility
    21st Sep 2026, 12:17 PM

    The inspection concluded with the issuance of a Form FDA 483 containing five observations

    Read More
  • Cohance Lifesciences receives four observations from USFDA for Telangana FDF plant
    7th Sep 2026, 10:28 AM

    The USFDA conducted an inspection of the said plant from August 27 to September 4, 2026

    Read More
  • Cohance Lifesciences receives five observations from USFDA for Pashamylaram facility
    6th Aug 2026, 12:41 PM

    USFDA has conducted an inspection from July 27, 2026, to August 5, 2026 at the said facility

    Read More
  • Cohance Lifesciences - Quarterly Results
    6th Aug 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.